Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixivaptan for euvolemic hyponatremia (SIADH) – randomized double-blind placebo-controlled Phase 3 trial
2006-001754-26Phase 3Completed
- Sponsor
- CardioKine
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyponatraemia and syndrome of inappropriate antidiuresis (SIAD) comparing Lixivaptan with Placebo (2 arms). Primary endpoint: Change in serum sodium concentration at day 7 (baseline serum sodium <130 mEq/L). Started Jan 2009; status: completed.
02
Drugs
lixivaptan
03
Conditions
hyponatraemiasyndrome of inappropriate antidiuresis (SIAD)
Beyond the preview
Go deeper on 2006-001754-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001754-26.